These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V. Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306 [Abstract] [Full Text] [Related]
5. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, Ozder A, Gulay Z, Camsari T. Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916 [Abstract] [Full Text] [Related]
10. Do central venous catheters have advantages over arteriovenous fistulas or grafts? Quarello F, Forneris G, Borca M, Pozzato M. J Nephrol; 2006; 19(3):265-79. PubMed ID: 16874685 [Abstract] [Full Text] [Related]
11. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site. Uttley L, Vardhan A, Mahajan S, Smart B, Hutchison A, Gokal R. J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524 [Abstract] [Full Text] [Related]
13. Preventing catheter-related infections in children undergoing hemodialysis. Stefanidis CJ. Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1239-49. PubMed ID: 21073289 [Abstract] [Full Text] [Related]
14. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Solomon LR, Cheesbrough JS, Ebah L, Al-Sayed T, Heap M, Millband N, Waterhouse D, Mitra S, Curry A, Saxena R, Bhat R, Schulz M, Diggle P. Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458 [Abstract] [Full Text] [Related]
15. The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW, HONEYPOT Study Collaborative Group. Perit Dial Int; 2015 Dec; 35(7):712-21. PubMed ID: 26224790 [Abstract] [Full Text] [Related]
16. [Prophylaxis and management of catheter-associated infections in peritoneal dialysis patients: recent studies and guidelines]. Kopriva-Altfahrt G, Moser E, Prokschi A, Kraus B, Kovarik J. Wien Klin Wochenschr; 2005 Dec; 117 Suppl 6():73-82. PubMed ID: 16437337 [Abstract] [Full Text] [Related]
17. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis. Cavdar C, Atay T, Zeybel M, Celik A, Ozder A, Yildiz S, Gulay Z, Camsari T. Adv Perit Dial; 2004 Dec; 20():67-70. PubMed ID: 15384798 [Abstract] [Full Text] [Related]
18. Predictors of hemodialysis central venous catheter exit-site infections. Harwood L, Wilson B, Thompson B, Brown E, Young D. CANNT J; 2008 Dec; 18(2):26-35. PubMed ID: 18669009 [Abstract] [Full Text] [Related]
19. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis. Mahaldar A, Weisz M, Kathuria P. Adv Perit Dial; 2009 Dec; 25():56-9. PubMed ID: 19886318 [Abstract] [Full Text] [Related]